



PATENT
Customer No. 22,852
Attorney Docket No. 09605.0002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Bernat VIDAL JUAN et al.) Group Art Unit: 1624
)
Application No.: 10/509,280) Examiner: Susanna Moore
)
§371 Filing date: May 5, 2005) Confirmation No.: 7655
)
For: NEW-4-(PYRROLOPYRIMIDIN-6-)
YL)BENZENESULPHONAMIDE)
DERIVATIVES)

Sir:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

TERMINAL DISCLAIMER

Assignee, Laboratorios Almirall S.A., duly organized under the laws of Spain and having its principal place of business at Ronda del General Mitre 155, Barcelona Spain, represents that it is the assignee of the entire right, title and interest in and to the above-identified application, Application No. 10/509,280, having a §371 Filing date of May 5, 2005 for New-4-(pyrrolopyrimidin-6-Yl)benzenesulphonamide Derivatives in the name of Bernat VIDAL JUAN and Cristina ESTEVE TRIAS, as indicated by the assignment duly recorded in the United States Patent and Trademark Office at Reel 018786, Frame 0571 on January 22, 2007. Assignee, Laboratorios Almirall S.A., further represents that it is the assignee of the entire right, title and interest in and to U.S.

05/31/2007 AWONDAF1 00000030 060916 10509280
01 FC:1814 130.00 DA

Patent Application No. 10/481,728, as indicated by the assignment to Almirall Prodesfarma S.A. duly recorded in the United States Patent and Trademark Office at Reel 015262, Frame 0470 on October 19, 2004. Almirall Prodesfarma S.A. later changed its name to Laboratorios Almirall S.A., as indicated in the documents submitted with the assignment cited above for Application No. 10/509,280, and which was recorded at Reel 018786, Frame 0571 on January 22, 2007.

To obviate a double patenting rejection, Assignee hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. §§ 154 to 156 and 173, as presently shortened by any terminal disclaimer, of the patent that may issue from Application No. 10/481,728, Assignee hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the patent that may issue from Application No. 10/481,728 are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, Assignee does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §§ 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that the prior patent later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or in part, is terminally disclaimed under 37 C.F.R. § 1.321, has all claims canceled by a reexamination

certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.


In accordance with the fee schedule set forth in 37 C.F.R. § 1.20(d), the required fee of \$130.00 is being filed with this disclaimer.

If a check for the required fee is not filed concurrently herewith or if there are any additional fees due in connection with the filing of this Terminal Disclaimer, please charge the fees to Deposit Account No. 06-0916. If a fee is required for an extension of time under 37 C.F.R. § 1.136 not accounted for above, such an extension is requested and the fee should also be charged to Deposit Account No. 06-0916.

The undersigned is an attorney of record.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

By: 

Carlos M. Téllez
Reg. No. 48,638

Dated: May 29, 2007